Michael A. Metzger - Dec 16, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Dec 16, 2021
Transactions value $
-$1,050,501
Form type
4
Date filed
12/20/2021, 05:44 PM
Previous filing
Dec 15, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $145K +22.7K +128.63% $6.38 40.4K Dec 16, 2021 Direct
transaction SNDX Common Stock Sale -$433K -22.7K -56.26% $19.08 17.7K Dec 16, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $10.7K +1.68K +9.49% $6.38 19.3K Dec 17, 2021 Direct
transaction SNDX Common Stock Sale -$31.9K -1.68K -8.67% $19.02 17.7K Dec 17, 2021 Direct F1, F3
transaction SNDX Common Stock Options Exercise $102K +16K +90.61% $6.38 33.7K Dec 20, 2021 Direct
transaction SNDX Common Stock Sale -$325K -16K -47.54% $20.29 17.7K Dec 20, 2021 Direct F1, F4
transaction SNDX Common Stock Options Exercise $395K +45K +254.83% $8.77 62.7K Dec 20, 2021 Direct
transaction SNDX Common Stock Sale -$913K -45K -71.82% $20.29 17.7K Dec 20, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -22.7K -100% $0.00* 0 Dec 16, 2021 Common Stock 22.7K $6.38 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -1.68K -100% $0.00* 0 Dec 17, 2021 Common Stock 1.68K $6.38 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -45K -100% $0.00* 0 Dec 20, 2021 Common Stock 45K $8.77 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16K -100% $0.00* 0 Dec 20, 2021 Common Stock 16K $6.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $19.00 to $19.30.
F3 The sale prices ranged from $19.00 to $19.06.
F4 The sale prices ranged from $19.17 to $21.01
F5 This option is fully vested.